Welcome to the House Committee on Energy and Commerce

WASHINGTON, D.C.  – Today, Congressman Brett Guthrie (KY-02), Chairman of the House Committee on Energy and Commerce, released the following statement after President Donald Trump signed three resolutions of disapproval under the Congressional Review Act, which repeal disastrous electric vehicle (EV) mandates.  “By rejecting EV mandates, the signing of these resolutions is a victory for American consumers who reject government mandates and one-size-fits-all policies,”  said Chairman Guthrie.  “Without this repeal, the special rules for California would have led to higher prices on both new and used vehicles, furthered our dependence on China, and overwhelmed our already-strained electric grid. Instead, Congressional Republicans and President Trump are standing up for American consumers by rolling back the worst policies of the Biden-Harris Administration. Thank you to Vice Chairman Joyce, Congressman Obernolte, and Congressman James for your work to ensure that families and businesses can continue choosing the vehicles they need.” Read an Op-Ed from Chairman Guthrie, Vice Chairman Joyce, Congressman James, and Congressman Obernolte on these resolutions  here . Background: The Clean Air Act generally preempts individual states from setting their own vehicle emission standards. However, section 209 of the Clean Air Act allows the Environmental Protection Agency to waive state preemption for California. This carveout was intended to allow California to implement stricter air vehicle emission standards to address “compelling and extraordinary circumstances” involving local air pollution – not to remake the auto industry and limit consumer choice nationwide. The Biden-Harris EPA granted these waivers that have allowed California to ban sales of new gas, diesel, and hybrid vehicles, as well as heavy-duty trucks, while also mandating 100% electric vehicle sales by 2035. H.J. Res. 88, led by Rep. John Joyce (PA-13), Vice Chairman of the House Committee on Energy and Commerce, repeals California’s Advanced Clean Cars II (ACCII) waiver, which would have the State to ban the sale of gas-powered vehicles by 2035. H.J. Res. 87, led by Rep. John James (MI-10), repeals California’s Advanced Clean Trucks (ACT) waiver, which would have allowed the State to mandate the sale of zero-emission trucks. H.J. Res. 89, led by Rep. Jay Obernolte (CA-23), puts an end to California’s implementation of its most recent nitrogen oxide (NOx) engine emission standards, which would have created burdensome and unworkable standards for heavy-duty, on-road engines. ###

WASHINGTON, D.C.  – Congressman Gus Bilirakis (FL-12), Chairman of the Subcommittee on Commerce, Manufacturing, and Trade, delivered the following opening statement at today’s hearing titled  Winning Off the Field: Legislative Proposal to Stabilize NIL and College Athletics. Subcommittee Chairman Bilirakis' opening statement as prepared for delivery: “Good morning, everyone, and welcome to our legislative hearing on Name, Image, and Likeness in college athletics.  “I want to thank our witnesses for being here today. Your experience and insight are critical as we navigate what is arguably one of the most transformative moments in the history of college sports.  “In recent years, we’ve seen a dramatic shift in how college athletes engage with their sports, their schools, and their personal brands. The recent House v. NCAA settlement represents more than just a court decision — it marks a fundamental change in how college athletics will operate going forward. The timing couldn’t be more appropriate for legislative action. “That’s why I am leading the SCORE Act — the Student Compensation and Opportunity through Rights and Endorsements Act — a comprehensive, commonsense discussion draft that reflects months of dialogue with student-athletes, athletic directors, conference leaders, and the NCAA.  “This is not just another proposal; it's a targeted solution designed to bring predictability, fairness, and long-term balance to a system that has rapidly evolved without structure. “The SCORE Act is built around three core principles:  Clarity: by establishing a national standard that replaces the current patchwork of state laws Stability: by setting reasonable guardrails around the transfer portal and NIL deals to protect both athletes and programs, and Support: by ensuring benefits like scholarship protections and financial literacy programs are not optional but expected. “For too long, student-athletes have operated in a gray area, empowered in some ways but exposed in others. The current model lacks the transparency and consistency that both athletes and institutions need. The SCORE Act brings that balance. “And while today’s hearing is just the beginning of a broader tri-committee process, with the Committees on Judiciary and Education & Workforce, it’s an important step. We are not here to micromanage college sports. We are here to put forward a framework that strengthens it — that ensures athletes can succeed on the field without losing sight of their futures off of it. “I am proud of the work this subcommittee has done on this issue, and I look forward to working with my colleagues on both sides of the aisle to get this across the finish line. And Go Gators!” ###

WASHINGTON, D.C.  – Congressman Buddy Carter (GA-01), Chairman of the Subcommittee on Health, delivered the following opening statement at today’s hearing titled  Made In America: Strengthening Domestic Manufacturing And The Health Care Supply Chain. Subcommittee Chairman Carter's opening statement as prepared for delivery: “Today’s hearing is critical in addressing our nation’s reliance on adversarial countries for essential medications and health care products. This dependence not only jeopardizes our national security and patient safety, but also highlights the urgent need to increase domestic and friend-shored manufacturing. “Let me be clear: the United States should never be dependent on the Chinese Communist Party for the antibiotics and essential medicines. But that’s exactly the dangerous position we are in today. “In 2002, the United States manufactured 72 percent of the pharmaceuticals it consumed. By 2023, that number had dropped to just 37.5 percent. We didn’t just outsource manufacturing—we outsourced the sovereignty and safety of our health care system. “We saw the impacts of this reliance firsthand during the COVID-19 pandemic. According to a conversation I had with the Administration for Strategic Preparedness and Response, or ASPR, under the Trump Administration, the United States saw a downtick in the amount of PPE and pharmaceuticals coming to our country from China in the fall of 2019. We didn’t learn about COVID-19 until January 2020. “China knew there was an unidentified sickness in its own country, concealed it, and then withheld medical supplies so the United States was less prepared when COVID-19 hit our shores. “As both a pharmacist and a member of Congress, I know how critical these medicines and supplies are — especially for our national security. Under the Biden-Harris Administration, over 323 drugs were in shortage during the first quarter of 2024 – an all-time high – and cancer patients were often forced to switch treatments, adjust dosage regimens, or, in extreme cases, unable to receive their lifesaving medications. There was no comprehensive effort to support American manufacturers or reduce our reliance on foreign supply chains. “That is unacceptable. “Thankfully, President Trump is taking meaningful action by demanding real investment in our domestic production base and putting an end to decades of failed “America Last” policies that left our supply chains hollowed out and put our patients, constituents, and families at risk. “Under the leadership of President Trump, we are bringing manufacturing back to America. Since the start of this year – the start of President Trump’s second term – Johnson & Johnson broke ground on a new $2 billion facility in North Carolina, Amgen announced a $900 million manufacturing expansion in Ohio, AbbVie committed $10 billion to invest in the United States, and Sanofi announced plans to invest at least $20 billion.  “And these are just a few examples. This is just the start.  “I look forward to hearing from my other colleagues about the recent investments in their Districts and States during this hearing today, and I am thrilled to see what additional investments continue to flow and thrive under an Administration focused on unleashing innovation and bringing capacities back home.  “Along those lines, I commend recent efforts by this Administration to bolster domestic production, but we must do our part in Congress as well. This hearing will make it clear that more can be done to eliminate burdensome regulatory barriers, streamline processes that impede our competitiveness on the global stage, and establish the proper incentives to ensure we are creating the environment to allow innovation to flourish.  “It is no coincidence that Georgia – the No. 1 state in the nation to do business – is home to Manus Bio, who has invested nearly $60 million and created over 100 jobs with the acquisition of a new manufacturing facility in Augusta. We need more policies at the federal level that mirror the pro-growth examples we have in the state of Georgia.  “That is why House Republicans passed the One Big Beautiful Bill Act, which incentivizes domestic medical supply production by rewarding companies that build their products in America, like USAntibiotics, who is the last remaining end-to-end domestic U.S. manufacturer of amoxicillin, the most prescribed antibiotic in the country.  This is about protecting American lives, empowering American workers, restoring American sovereignty, and reinforcing U.S. leadership in medical innovation. “China is not our friend. Every product component that then turns into a vial of medicine or a piece of medical equipment that is made in China is a missed opportunity to strengthen our economy and protect our people. “It is time to act. We need to view pharmaceutical and health care supply chain independence just as we are viewing energy independence. I am proud to stand with President Trump and all those committed to putting America First in our health care system—starting with the medicines we rely on every day.” ###

WASHINGTON, D.C.  – Today, Congressman Brett Guthrie (KY-02), Chairman of the House Committee on Energy and Commerce, Congressman Richard Hudson (NC-09), Chairman of the Subcommittee on Communications and Technology, sent a letter to President Donald J. Trump urging the administration to quickly remove burdensome regulations that have stopped the Broadband Equity, Access, and Deployment (BEAD) program from connecting any American to reliable broadband. KEY EXCERPT: “The Biden administration added unnecessary and burdensome requirements that made participation in the program more expensive and less attractive to broadband providers. These include labor and climate change requirements, as well as rate regulation of low-cost broadband plans that were unlawfully imposed.  “To address these issues, we introduced the Streamlining Program Efficiency and Expanding Deployment (SPEED) for BEAD Act, which outlines necessary reforms to BEAD. We appreciate that Secretary of Commerce Howard Lutnick is undertaking a review of the program and urge any reforms to be enacted as soon as possible.” BACKGROUND: On March 5, 2025,  Congressman Hudson introduced  the SPEED for BEAD Act to remove harmful regulations that have prevented the $42 billion program from laying even a single inch of fiber to support rural Americans. Also on March 5, 2025, the Committee on Energy and Commerce  held a hearing  to discuss the BEAD program titled  Fixing Biden’s Broadband Blunder. CLICK HERE to read the full letter. ###

WASHINGTON, D.C.  – Today, Congressman Brett Guthrie (KY-02), Chairman of the House Committee on Energy and Commerce, Congressman Gus Bilirakis (FL-12), Chairman of the Subcommittee on Commerce, Manufacturing, and Trade, and Congressman Gary Palmer (AL-06), Chairman of the Subcommittee on Oversight and Investigations, sent a letter to 23andMe regarding the handling of Americans' sensitive data following the company's decision to file for bankruptcy. KEY EXCERPT: “According to 23andMe’s privacy statement, in a bankruptcy, customers’ ‘Personal Information may be accessed, sold or transferred as part of that transaction and this Privacy Statement will apply to [customer] Personal Information as transferred to the new entity.’ Additionally, a judge recently ruled 23andMe has the right to sell the sensitive medical and genetic information of its 15 million customers, which is considered to be the company’s most valuable asset. With the lack of a federal comprehensive data privacy and security law, we write to express our great concern about the safety of Americans’ most sensitive personal information.” Background: On March 23, 2025, 23andMe initiated Chapter 11 bankruptcy proceedings, which could have ramifications for the highly sensitive information of millions of Americans. While Americans’ personal health information is protected under the Health Insurance Portability and Accountability Act (HIPAA), these protections only apply if the information is collected by a HIPAA covered entity. Generally, direct-to-consumer companies, like 23andMe, are not covered by HIPAA. Customers have reported issues accessing and deleting their data from their 23andMe accounts. The Chairmen have requested answers to the following questions: If 23andMe were to sell the personal information of its customers either as a standalone asset or as part of a broader sale of the company, what post-sale data privacy and security protections would be in place for its customers’ personal information? Please describe how the representations made in 23andMe’s privacy statement will continue to apply—and be enforced—if the personal information of 23andMe’s customers is sold to a third party. Please include in this response information about what, if anything, would hold a third-party buyer to 23andMe’s privacy statement or prevent it from subsequently using, transferring, or otherwise selling, such information in the future. Does 23andMe plan to change its privacy statement at any time prior to selling any customers’ personal information? If so, please explain the change 23andMe plans to implement and when those changes will go into effect. Does 23andMe intend to vet prospective buyers to which it may sell its customers’ personal information? If so, please detail the vetting process and whether it will include the prospective buyer’s history of implementing data security protections and compliance with sectoral, state, or any other data privacy and security laws. If not, please explain why. Please detail the categories of customer information 23andMe has, and of that what 23andMe is considering selling. Has 23andMe notified its customers of the company’s bankruptcy announcement? If so, please attach the customer notification. If not, please explain why. Has 23andMe provided its customers with a guide for how to delete, or request to delete any information currently in 23andMe’s possession? If so, please provide a copy of that guide and specify when it was provided to customers. If not, please explain why, and explain whether 23andMe will contact each of its customers and provide an opportunity to delete their personal information prior to a potential sale of the company or personal information maintained by the company. Please detail the number of requests 23andMe received from its customers to delete their personal information between when 23andMe filed for bankruptcy and the date of the response to this letter. Of those requests, please provide a breakdown of how many requests were made by customers through their 23andMe online accounts and how many were made via customer service calls because customers were unable to successfully delete their information through their online accounts. Of those requests, please detail the number of fulfilled requests. Will 23andMe offer for sale any information in which a customer has requested the deletion of such information? If so, does 23andMe’s privacy policy consider selling information a legitimate purpose for retaining information past a customer's request to delete their information? Will 23andMe deidentify its customers’ personal information prior to selling it or the company? If so, please detail which information will be deidentified. If not, please explain why the company is electing not to deidentify information. CLICK HERE to read the full letter. CLICK HERE to read the story from CNBC. ###

WASHINGTON, D.C. – This week, Congressman Brett Guthrie (KY-02), Chairman of the House Committee on Energy and Commerce, Congressman Gary Palmer (AL-06), Chairman of the Subcommittee on Oversight and Investigations, and Congressman Morgan Griffith (VA-09), Chairman of the Subcommittee on Environment, wrote letters to eight Greenhouse Gas Reduction Fund (GGRF) grant recipients. “The Committee has had concerns about the GGRF program—including the program’s unusual structure and a potential lack of due diligence in selecting award recipients. A recent Oversight and Investigations Subcommittee hearing examined these issues and the speed with which money was pushed out the door by the Biden Administration’s EPA, which raised additional questions about certain GGRF recipients.” said Chairmen Guthrie, Palmer, and Griffith. “ This investigation is key to evaluating whether these funds were awarded fairly and impartially to qualified applicants and determining how the federal funds are being used.” Background:  The Inflation Reduction Act (IRA) authorized the Environmental Protection Agency (EPA) to create and implement a $27 billion GGRF program. Of this appropriation, $20 billion was awarded to just eight grant recipients; with $14 billion awarded to three grant recipients under the National Clean Investment Fund (NCIF) program and $6 billion awarded to five grant recipients under the Clean Communities Investment Accelerator (CCIA) program.    Letters: National Clean Investment Fund Program Recipients Coalition for Green Capital Climate United Fund Power Forward Communities   Clean Communities Investment Accelerator Program Recipients Justice Climate Fund Opportunity Finance Network Inclusiv Native CDFI Network Appalachian Community Capital Read the story here . ###